Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
4 hedge funds and large institutions have $26.7K invested in Altamira Therapeutics Ltd in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 6 closing their positions.
50% less funds holding
Funds holding: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
88% less capital invested
Capital invested by funds: $217K → $26.7K (-$191K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$29.7K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$203K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9.45K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.46K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.44K |
| 5 |
Morgan Stanley
New York
|
-$122 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $23.7K | +$29.7K | +6,814 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $2.96K | +$3.7K | +851 | New |
|
3
Group One Trading
Chicago,
Illinois
| $49 | -$4 | -1 | -7% |
|
4
Wells Fargo
San Francisco,
California
| $3 | – | – | – |
|
|
AC
5
Armistice Capital
New York
| – | -$203K | -41,450 | Closed |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$9.45K | -1,958 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$2.46K | -509 | Closed |
|
|
XT
8
XTX Topco
George Town,
Cayman Islands
| – | -$2.44K | -507 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$122 | -25 | Closed |
|
|
SCA
10
Stonebridge Capital Advisors
St Paul,
Minnesota
| – | -$1 | – | – |
|
CYTO Hedge Fund Activity: Q4 2023 in Review
4 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2023, worth a combined $26.7K — down 88% from $217K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CYTO and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $29.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $203K sold.
- 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2023, down from 8 in Q3 2023.
- Funds reported $26.7K of Altamira Therapeutics Ltd stock for Q4 2023, down 88% quarter-over-quarter.
- 2 funds opened new Altamira Therapeutics Ltd positions in Q4 2023 and 6 closed out, a net change of -4 holders.
- The largest Altamira Therapeutics Ltd buyer in Q4 2023 was UBS Group, an estimated $29.7K added.
- The largest Altamira Therapeutics Ltd seller in Q4 2023 was Armistice Capital, an estimated $203K sold.
Based on aggregated 13F filings for Q4 2023.